UCARE 2023 Symposium: Targeting Type 2 Inflammation in CSU – Clinical and Mechanistic Implications
Exploring the role of type 2 inflammation and the neuroimmune axis in CSU, and how emerging therapeutics are targeting key molecules in these pathways.
On demand materials
Learning objectives
- Enhance awareness of emerging clinical trial data in CSU
- Learn about the role of type 2 inflammation in the pathogenesis of CSU
- Explore the role of the neuroimmune axis in CSU
Description
Symposium focusing on the key roles of type 2 inflammation and the neuroimmune axis in CSU pathophysiology. Current understanding of these pathways has guided development of emerging therapeutics that target molecular drivers within type 2 inflammation, from which Phase 3 efficacy and safety data are presented and explored. Dr. Ensina guides discussions on the perspective of CSU management in Brazil. Dr. Maurer explores current clinical data from leading emerging therapies in CSU. Drs. Saini and Kim provide a deep dive into the pathophysiology of type 2 inflammation and the neuroimmune axis in CSU.
About these experts
